Related Experiment Video

Updated: Jun 23, 2026

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time

Am Young1, Iain A McNeish

  • 1Centre for Molecular Oncology & Imaging, Institute of Cancer, Barts & The London School of Medicine & Dentistry, Charterhouse Square, London EC1M 6BQ, UK.

Future Oncology (London, England)
|April 21, 2009
PubMed

Insights

Gene therapy for ovarian cancer has shown promise in preclinical studies but faced clinical disappointments. Current research applies lessons learned to improve treatment options for this challenging disease.

Area of Science:

  • Oncology
  • Gene Therapy
  • Ovarian Cancer Research

Background:

  • Preclinical gene therapy studies have historically shown significant promise for various cancers.
  • Despite early hopes, clinical trials for gene therapy, particularly in oncology, have frequently yielded disappointing results.
  • Ovarian cancer presents a critical unmet need due to poor response rates to conventional chemotherapy and high rates of refractory disease.

Purpose of the Study:

  • To review the current status of gene therapy in the context of ovarian cancer treatment.
  • To analyze the reasons behind the historically discouraging clinical trial outcomes for ovarian cancer gene therapy.
  • To discuss how insights from past trials are informing ongoing and future gene therapy research for ovarian cancer.

Main Methods:

  • Literature review of preclinical and clinical gene therapy studies in ovarian cancer.
  • Analysis of factors contributing to trial failures and successes.
  • Examination of evolving strategies in current gene therapy research for ovarian cancer.

Main Results:

  • Gene therapy has demonstrated potential in preclinical ovarian cancer models.
  • Numerous clinical trials have failed to translate preclinical promise into significant patient benefit.
  • Specific challenges in ovarian cancer, such as tumor microenvironment and delivery, have hindered progress.

Conclusions:

  • The translation of gene therapy from preclinical success to clinical efficacy in ovarian cancer remains a significant challenge.
  • Understanding the limitations and failures of earlier trials is crucial for developing more effective gene therapy strategies.
  • Ongoing research aims to overcome previous hurdles by refining delivery methods, patient selection, and therapeutic targets for ovarian cancer.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...